| __timestamp | Taro Pharmaceutical Industries Ltd. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 91733000 | 40786000 |
| Thursday, January 1, 2015 | 87644000 | 47876000 |
| Friday, January 1, 2016 | 92365000 | 52035000 |
| Sunday, January 1, 2017 | 85656000 | 55348000 |
| Monday, January 1, 2018 | 88196000 | 65276000 |
| Tuesday, January 1, 2019 | 89971000 | 82720000 |
| Wednesday, January 1, 2020 | 93413000 | 89118000 |
| Friday, January 1, 2021 | 91355000 | 181193000 |
| Saturday, January 1, 2022 | 113676000 | 174078000 |
| Sunday, January 1, 2023 | 198366000 | 184232000 |
| Monday, January 1, 2024 | 218935000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Veracyte, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro's SG&A expenses have shown a steady increase, peaking at approximately 218% of their 2014 value by 2023. In contrast, Veracyte's expenses surged dramatically, reaching nearly 452% of their 2014 levels by 2022, before data became unavailable in 2023. This trend highlights Veracyte's aggressive expansion strategy, while Taro maintains a more conservative growth approach. The absence of Veracyte's 2024 data suggests a potential shift or reevaluation in their financial strategy. Investors and industry analysts should consider these trends when evaluating the companies' future growth and market positioning.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Veracyte, Inc.
Alnylam Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.
Amneal Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends